{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:54:17Z","timestamp":1790009657399,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403874"],"award-info":[{"award-number":["82403874"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20241203"],"award-info":[{"award-number":["BK20241203"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024T170397"],"award-info":[{"award-number":["2024T170397"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741629"],"award-info":[{"award-number":["2023M741629"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019334","name":"Key Project of Science and Technology Development of Nanjing Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Innovation"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xinn.2026.101357","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:35:41Z","timestamp":1774683341000},"page":"101357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Xinyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-5808","authenticated-orcid":false,"given":"Xiaosu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9209-1004","authenticated-orcid":false,"given":"Lifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-5783","authenticated-orcid":false,"given":"Shuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1851-7430","authenticated-orcid":false,"given":"Fangjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xinn.2026.101357_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","article-title":"Challenges in neoantigen-directed therapeutics","volume":"41","author":"Lybaert","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xinn.2026.101357_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xinn.2026.101357_bib3","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.celrep.2019.07.106","article-title":"Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood","volume":"28","author":"Peng","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.xinn.2026.101357_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy","volume":"615","author":"Puig-Saus","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2026.101357_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101357_bib7","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xinn.2026.101357_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41577-020-0406-2","article-title":"Lactate modulation of immune responses in inflammatory versus tumour microenvironments","volume":"21","author":"Certo","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xinn.2026.101357_bib10","article-title":"Neoantigen: A New Breakthrough in Tumor Immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101357_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1574958","article-title":"Bispecific antibody targeting shared indel-derived neoantigen of APC","volume":"16","author":"Effenberger","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101357_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13059-023-03005-9","article-title":"Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors","volume":"24","author":"Shi","year":"2023","journal-title":"Genome Biol."},{"key":"10.1016\/j.xinn.2026.101357_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008988","article-title":"Comprehensive profiling of cancer neoantigens from aberrant RNA splicing","volume":"12","author":"Wickland","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101357_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.522588","article-title":"Circular RNA CircFAM188B Encodes a Protein That Regulates Proliferation and Differentiation of Chicken Skeletal Muscle Satellite Cells","volume":"8","author":"Yin","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.xinn.2026.101357_bib15","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2016.09.022","article-title":"Beyond the Triplet Code: Context Cues Transform Translation","volume":"167","author":"Brar","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101357_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fimmu.2017.00689","article-title":"Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators","volume":"8","author":"Qin","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101357_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1492508","article-title":"Predicting T cell recognition of MHC class I restricted neoepitopes","volume":"7","author":"Ko\u015falo\u011flu-Yal\u00e7\u0131n","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xinn.2026.101357_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12967-025-06094-1","article-title":"Identification of novel KRAS(G12D) neoantigen specific TCRs and a strategy to eliminate off-target recognition","volume":"23","author":"Han","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100856","article-title":"Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth","volume":"13","author":"Das","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xinn.2026.101357_bib20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/neuonc\/nox232","article-title":"Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma","volume":"20","author":"Mahlokozera","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xinn.2026.101357_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/0008-5472.CAN-18-1086","article-title":"Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.xinn.2026.101357_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2026.101357_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-05134-6","article-title":"A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy","volume":"15","author":"Goloudina","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xinn.2026.101357_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101357_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41420-021-00607-9","article-title":"Whole exome and transcriptome sequencing reveal clonal evolution and exhibit immune-related features in metastatic colorectal tumors","volume":"7","author":"Li","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101357_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","article-title":"Probiotic neoantigen delivery vectors for precision cancer immunotherapy","volume":"635","author":"Redenti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002595","article-title":"Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing","volume":"9","author":"Lu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101357_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado5600","article-title":"Large-scale transcript variants dictate neoepitopes for cancer immunotherapy","volume":"11","author":"Ji","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xinn.2026.101357_bib29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib30","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1172\/JCI99538","article-title":"Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xinn.2026.101357_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2026.101357_bib32","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xinn.2026.101357_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xinn.2026.101357_bib34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101357_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs","volume":"50","author":"Rammensee","year":"1999","journal-title":"Immunogenetics"},{"key":"10.1016\/j.xinn.2026.101357_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cels.2022.12.002","article-title":"Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+) T-cell epitopes","volume":"14","author":"Gfeller","year":"2023","journal-title":"Cell Syst."},{"key":"10.1016\/j.xinn.2026.101357_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature22976","article-title":"Identifying specificity groups in the T cell receptor repertoire","volume":"547","author":"Glanville","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature22383","article-title":"Quantifiable predictive features define epitope-specific T cell receptor repertoires","volume":"547","author":"Dash","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s42003-023-04749-7","article-title":"Machine learning reveals limited contribution of trans-only encoded variants to the HLA-DQ immunopeptidome","volume":"6","author":"Nilsson","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xinn.2026.101357_bib40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s42003-025-08500-2","article-title":"HLAIIPred: cross-attention mechanism for modeling the interaction of HLA class II molecules with peptides","volume":"8","author":"Haghighatlari","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xinn.2026.101357_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.664514","article-title":"Contribution of T Cell Receptor Alpha and Beta CDR3, MHC Typing, V and J Genes to Peptide Binding Prediction","volume":"12","author":"Springer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101357_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa318","article-title":"Current challenges for unseen-epitope TCR interaction prediction and a new perspective derived from image classification","volume":"22","author":"Moris","year":"2021","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.xinn.2026.101357_bib43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s42256-021-00383-2","article-title":"Deep learning-based prediction of the T cell receptor-antigen binding specificity","volume":"3","author":"Lu","year":"2021","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.xinn.2026.101357_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xinn.2026.101357_bib45","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101357_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101357_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib49","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/d41591-023-00072-0","article-title":"Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xinn.2026.101357_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xinn.2026.101357_bib53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xinn.2026.101357_bib54","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib55","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41467-024-44776-4","article-title":"Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia","volume":"15","author":"Gurbatri","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101357_bib56","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cell.2025.02.002","article-title":"Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization","volume":"188","author":"Chang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101357_bib57","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.add9667","article-title":"Engineering bacteria as interactive cancer therapies","volume":"378","author":"Gurbatri","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101357_bib58","article-title":"Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric\/Gastroesophageal Junction Cancer","volume":"10","author":"Liu","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101357_bib59","article-title":"NIR-Triggered Phototherapy and Immunotherapy via an Antigen-Capturing Nanoplatform for Metastatic Cancer Treatment","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101357_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202208546","article-title":"DNA Nanoclusters Combined with One-Shot Radiotherapy Augment Cancer Immunotherapy Efficiency","volume":"35","author":"Xie","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xinn.2026.101357_bib61","article-title":"In Situ Antigen-Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy","volume":"18","author":"Li","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.xinn.2026.101357_bib62","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1038\/s41467-021-25197-z","article-title":"An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101357_bib63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41551-021-00834-6","article-title":"Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria","volume":"6","author":"Wang","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xinn.2026.101357_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002484","article-title":"Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist","volume":"9","author":"Sabree","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101357_bib65","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2026.101357_bib66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biomaterials.2017.08.017","article-title":"RGD peptide-modified fluorescent gold nanoclusters as highly efficient tumor-targeted radiotherapy sensitizers","volume":"144","author":"Liang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.xinn.2026.101357_bib67","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2026.101357_bib68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2026.101357_bib69","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1038\/s41591-025-03995-y","article-title":"A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial","volume":"31","author":"Baretti","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib70","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Al Bakir","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib71","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib72","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101357_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002531","article-title":"Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations","volume":"9","author":"Li","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101357_bib74","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib75","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.xinn.2026.101357_bib76","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xinn.2026.101357_bib77","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1038\/s41467-024-51315-8","article-title":"A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine","volume":"15","author":"Latzer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101357_bib78","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xinn.2026.101357_bib79","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101357_bib80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12967-022-03624-z","article-title":"Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination","volume":"20","author":"Ellingsen","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib81","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xinn.2026.101357_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2300881","article-title":"Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design","volume":"20","author":"Xin","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.xinn.2026.101357_bib83","article-title":"Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting","volume":"2","author":"Schmidt","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade2886","article-title":"Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy","volume":"16","author":"Li","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib85","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1038\/s41467-025-60461-6","article-title":"Identifying T cell antigen at the atomic level with graph convolutional network","volume":"16","author":"Que","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101357_bib86","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101357_bib87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.xinn.2026.101357_bib88","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.7150\/ijms.109515","article-title":"Radiotherapy elicits immunogenic cell death and metabolic shifts in the tumor microenvironment: implications for immunotherapy","volume":"22","author":"Hang","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.xinn.2026.101357_bib89","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xinn.2026.101357_bib90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.xinn.2026.101357_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202304609","article-title":"Radiotherapy-Induced Astrocyte Senescence Promotes an Immunosuppressive Microenvironment in Glioblastoma to Facilitate Tumor Regrowth","volume":"11","author":"Ji","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101357_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2025.101385","article-title":"Mitophagy: A key regulator of radiotherapy resistance in the tumor immune microenvironment","volume":"105","author":"Xia","year":"2025","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101357_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8707","article-title":"High-dose vitamin C enhances cancer immunotherapy","volume":"12","author":"Magr\u00ec","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xinn.2026.101357_bib95","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2021.12.039","article-title":"Magnesium sensing via LFA-1 regulates CD8(+) T cell effector function","volume":"185","author":"Lotscher","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101357_bib96","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1038\/s41467-022-33599-w","article-title":"Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer","volume":"13","author":"Kennedy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101357_bib97","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41563-022-01251-z","article-title":"STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity","volume":"21","author":"Dane","year":"2022","journal-title":"Nat. Mater."}],"container-title":["The Innovation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826001049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826001049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:52:41Z","timestamp":1788987161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666675826001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666675826001049"],"URL":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101357","relation":{},"ISSN":["2666-6758"],"issn-type":[{"value":"2666-6758","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"The Innovation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Youth Innovation Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101357"}}